Find Bictegravir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1611493-60-7, Gs-9883, Bictegravir [inn], Gs-9883-01, (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, 8gb79loj07
Molecular Formula
C21H18F3N3O5
Molecular Weight
449.4  g/mol
InChI Key
SOLUWJRYJLAZCX-LYOVBCGYSA-N
FDA UNII
8GB79LOJ07

Bictegravir
Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
1 2D Structure

Bictegravir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide
2.1.2 InChI
InChI=1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1
2.1.3 InChI Key
SOLUWJRYJLAZCX-LYOVBCGYSA-N
2.1.4 Canonical SMILES
C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
2.1.5 Isomeric SMILES
C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
2.2 Other Identifiers
2.2.1 UNII
8GB79LOJ07
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bictegravir Sodium

2. Gs-9883

3. Gs-9883 Sodium

4. Gs-9883-01

5. Gs-9883-01 Sodium

2.3.2 Depositor-Supplied Synonyms

1. 1611493-60-7

2. Gs-9883

3. Bictegravir [inn]

4. Gs-9883-01

5. (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide

6. 8gb79loj07

7. (1s,11r,13r)-5-hydroxy-3,6-dioxo-n-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide

8. 2,5-methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-n-((2,4,6-trifluorophenyl)methyl)-, (2r,5s,13ar)-

9. Bictegravir [usan:inn]

10. Bictegravirum

11. Unii-8gb79loj07

12. Gs 9883

13. Bictegravir [mi]

14. Bictegravir (usan/inn)

15. Bictegravir [usan]

16. Bictegravir [who-dd]

17. Chembl3989866

18. Schembl15914278

19. Gtpl11575

20. Chebi:172943

21. Bdbm330048

22. Dtxsid701027937

23. Amy12383

24. Bcp25703

25. Ex-a3161

26. Gs9883

27. S5911

28. Db11799

29. Dt-0020

30. Ac-30658

31. Hy-17605

32. Cs-0014685

33. D10909

34. N16998

35. Us9663528, 42

36. A902376

37. Q27270406

38. Gs-9883; Gs 9883; Gs9883; Gs-9883-01

39. (1s,11r,13r)-5-hydroxy-3,6-dioxo-n-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0(2),(1)(1).0?,?]hexadeca-4,7-diene-7-carboxamide

40. (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazepine-10-carboxamide

2.4 Create Date
2015-02-13
3 Chemical and Physical Properties
Molecular Weight 449.4 g/mol
Molecular Formula C21H18F3N3O5
XLogP32.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count3
Exact Mass449.11985517 g/mol
Monoisotopic Mass449.11985517 g/mol
Topological Polar Surface Area99.2 Ų
Heavy Atom Count32
Formal Charge0
Complexity912
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Bictegravir is indicated in the management of HIV-1 infection in patients not previously treated with antiretroviral therapy. Additionally, Bictegravir is indicated in the management of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA <50 c/mL) on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication. It is used in combination with tenofovir and emtricitabine.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Bictegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Bictegravir (BIC) inhibits HIV-1 virus replication into the human genome. It can be taken once daily without additional dosing. Bictegravir (BIC) inhibits strand transfer of viral DNA into the host genome and thereby prevents HIV-1 replication.


5.2 Absorption, Distribution and Excretion

Absorption

Bictegravir is rapidly absorbed within the body. Tmax= 2.0-4.0h [FDA LABEL, 1219]


Route of Elimination

BIC is mainly eliminated through UGT1A1 glucuronidation and CYP3A4 oxidation, equally. About 1% of the bictegravir dose is excreted in the urine, unchanged [1218,1219].


Volume of Distribution

0.2 L/Kg in humans


Clearance

Bictegravir is mainly cleared by the kidneys. Those with renal clearance <30 should not take bictegravir [FDA LABEL]


5.3 Metabolism/Metabolites

In a 10-day dose-ranging study, monotherapy (5 mg to 100 mg) once daily in adults who were not previously treated with bictegravir, the median half-life of BIC ranged from 15.9 h - 20.9 h [L1219. Bictegravir is metabolized in the liver and kidneys. CYP3A4 and UGT1A are the primary enzymes involved in the metabolism of bictegravir. Administration of bictegravir is not advised in patients with renal creatinine clearance of <30 mL/min and patients with hepatic disease [FDA LABEL].


5.4 Biological Half-Life

17. 3h [FDA LABEL, L1219]


5.5 Mechanism of Action

This single dose medication inhibits the strand transfer of viral DNA into the human genome, preventing HIV-1 virus replication and propagation. In vitro, bictegravir has shown powerful antiviral activity against HIV-2 and various subtypes of HIV-1. It has shown synergistic effects when combined with other ARVs, including tenofovir alafenamide (TAF), emtricitabine (FTC), and darunavir (DRV) [FDA LABEL]. The three components of the first USA approved medication ( trade name: Biktarvy ) are as follows: Bictegravir: integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme necessary for viral replication. Inhibition of the integrase enzyme prevents the integration of HIV-1 into host DNA, blocking the conversion of the HIV-1 provirus and progression of the virus [FDA LABEL]. Emtricitabine: FTC, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate intracellularly. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase by competing with the substrate deoxycytidine 5'-triphosphate and by incorporating itself into viral DNA preventing DNA chain elongation [FDA LABEL]. Tenofovir Alafenamide: TAF is a phosphonamidate prodrug of tenofovir (2-deoxyadenosine monophosphate analog). Plasma exposure to TAF leads to leakage into cells and then TAF is intracellularly converted to tenofovir by hydrolysis by cathepsin. Tenofovir is subsequently phosphorylated by cellular kinases to the metabolite tenofovir diphosphate, which is the active form of the drug. Tenofovir diphosphate inhibits HIV-1 replication by incorporating into viral DNA by the HIV reverse transcriptase, resulting in DNA chain-termination. Tenofovir diphosphate also weakly inhibits mammalian DNA polymerases [FDA LABEL].


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

ABOUT THIS PAGE

Bictegravir Manufacturers

A Bictegravir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bictegravir, including repackagers and relabelers. The FDA regulates Bictegravir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bictegravir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Bictegravir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Bictegravir Suppliers

A Bictegravir supplier is an individual or a company that provides Bictegravir active pharmaceutical ingredient (API) or Bictegravir finished formulations upon request. The Bictegravir suppliers may include Bictegravir API manufacturers, exporters, distributors and traders.

click here to find a list of Bictegravir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Bictegravir USDMF

A Bictegravir DMF (Drug Master File) is a document detailing the whole manufacturing process of Bictegravir active pharmaceutical ingredient (API) in detail. Different forms of Bictegravir DMFs exist exist since differing nations have different regulations, such as Bictegravir USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Bictegravir DMF submitted to regulatory agencies in the US is known as a USDMF. Bictegravir USDMF includes data on Bictegravir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bictegravir USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Bictegravir suppliers with USDMF on PharmaCompass.

Bictegravir NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bictegravir as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Bictegravir API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Bictegravir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Bictegravir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bictegravir NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Bictegravir suppliers with NDC on PharmaCompass.

Bictegravir GMP

Bictegravir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Bictegravir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bictegravir GMP manufacturer or Bictegravir GMP API supplier for your needs.

Bictegravir CoA

A Bictegravir CoA (Certificate of Analysis) is a formal document that attests to Bictegravir's compliance with Bictegravir specifications and serves as a tool for batch-level quality control.

Bictegravir CoA mostly includes findings from lab analyses of a specific batch. For each Bictegravir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Bictegravir may be tested according to a variety of international standards, such as European Pharmacopoeia (Bictegravir EP), Bictegravir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bictegravir USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty